Immune thrombocytopenia (ITP) is a bleeding disorder caused by thrombocytopenia not associated with a systemic disease. Typically, it is chronic in adults, but it is usually acute and self-limited in children. Spleen size is normal in the absence of another underlying condition.

The global market for Immune Thrombocytopenia Treatment was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Immune Thrombocytopenia Treatment, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Immune Thrombocytopenia Treatment by region & country, by Type, and by Application.

The Immune Thrombocytopenia Treatment market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Immune Thrombocytopenia Treatment.

Market Segmentation

Scope of Immune Thrombocytopenia Treatment - Market Report

Report Metric	Details
Report Name	Immune Thrombocytopenia Treatment - Market
CAGR	5%
Segment by Type:	Corticosteroids Intravenous Immunoglobulin (IVIG) Anti-D Immunoglobulin Thrombopoietin Receptor Agonist (TPO-RA) Others
Segment by Application	Hospitals and Clinics Research and Academic Institutes Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	CSL Behring, Amgen, F.Hoffmann-La Roche, Kyowa Hakko Kirin, Rigel Pharmaceuticals, Shionogi, Dova Pharmaceuticals, Novartis, Shire, Ligand Pharmaceuticals, GSK, Grifols Biologicals, Jiangsu Hengrui Pharmaceutical
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Immune Thrombocytopenia Treatment manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Immune Thrombocytopenia Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Immune Thrombocytopenia Treatment in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

FAQ for this report

Who are the main players in the Immune Thrombocytopenia Treatment - Market report?

Ans: The main players in the Immune Thrombocytopenia Treatment - Market are CSL Behring, Amgen, F.Hoffmann-La Roche, Kyowa Hakko Kirin, Rigel Pharmaceuticals, Shionogi, Dova Pharmaceuticals, Novartis, Shire, Ligand Pharmaceuticals, GSK, Grifols Biologicals, Jiangsu Hengrui Pharmaceutical

What are the Application segmentation covered in the Immune Thrombocytopenia Treatment - Market report?

Ans: The Applications covered in the Immune Thrombocytopenia Treatment - Market report are Hospitals and Clinics, Research and Academic Institutes, Others

What are the Type segmentation covered in the Immune Thrombocytopenia Treatment - Market report?

Ans: The Types covered in the Immune Thrombocytopenia Treatment - Market report are Corticosteroids, Intravenous Immunoglobulin (IVIG), Anti-D Immunoglobulin, Thrombopoietin Receptor Agonist (TPO-RA), Others

1 Market Overview

1.1 Immune Thrombocytopenia Treatment Product Introduction

1.2 Global Immune Thrombocytopenia Treatment Market Size Forecast

1.3 Immune Thrombocytopenia Treatment Market Trends & Drivers

1.3.1 Immune Thrombocytopenia Treatment Industry Trends

1.3.2 Immune Thrombocytopenia Treatment Market Drivers & Opportunity

1.3.3 Immune Thrombocytopenia Treatment Market Challenges

1.3.4 Immune Thrombocytopenia Treatment Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Immune Thrombocytopenia Treatment Players Revenue Ranking (2023)

2.2 Global Immune Thrombocytopenia Treatment Revenue by Company (2019-2024)

2.3 Key Companies Immune Thrombocytopenia Treatment Manufacturing Base Distribution and Headquarters

2.4 Key Companies Immune Thrombocytopenia Treatment Product Offered

2.5 Key Companies Time to Begin Mass Production of Immune Thrombocytopenia Treatment

2.6 Immune Thrombocytopenia Treatment Market Competitive Analysis

2.6.1 Immune Thrombocytopenia Treatment Market Concentration Rate (2019-2024)

2.6.2 Global 5 and 10 Largest Companies by Immune Thrombocytopenia Treatment Revenue in 2023

2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Immune Thrombocytopenia Treatment as of 2023)

2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 Corticosteroids

3.1.2 Intravenous Immunoglobulin (IVIG)

3.1.3 Anti-D Immunoglobulin

3.1.4 Thrombopoietin Receptor Agonist (TPO-RA)

3.1.5 Others

3.2 Global Immune Thrombocytopenia Treatment Sales Value by Type

3.2.1 Global Immune Thrombocytopenia Treatment Sales Value by Type (2019 VS 2023 VS 2030)

3.2.2 Global Immune Thrombocytopenia Treatment Sales Value, by Type (2019-2030)

3.2.3 Global Immune Thrombocytopenia Treatment Sales Value, by Type (%) (2019-2030)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Hospitals and Clinics

4.1.2 Research and Academic Institutes

4.1.3 Others

4.2 Global Immune Thrombocytopenia Treatment Sales Value by Application

4.2.1 Global Immune Thrombocytopenia Treatment Sales Value by Application (2019 VS 2023 VS 2030)

4.2.2 Global Immune Thrombocytopenia Treatment Sales Value, by Application (2019-2030)

4.2.3 Global Immune Thrombocytopenia Treatment Sales Value, by Application (%) (2019-2030)

5 Segmentation by Region

5.1 Global Immune Thrombocytopenia Treatment Sales Value by Region

5.1.1 Global Immune Thrombocytopenia Treatment Sales Value by Region: 2019 VS 2023 VS 2030

5.1.2 Global Immune Thrombocytopenia Treatment Sales Value by Region (2019-2024)

5.1.3 Global Immune Thrombocytopenia Treatment Sales Value by Region (2025-2030)

5.1.4 Global Immune Thrombocytopenia Treatment Sales Value by Region (%), (2019-2030)

5.2 North America

5.2.1 North America Immune Thrombocytopenia Treatment Sales Value, 2019-2030

5.2.2 North America Immune Thrombocytopenia Treatment Sales Value by Country (%), 2023 VS 2030

5.3 Europe

5.3.1 Europe Immune Thrombocytopenia Treatment Sales Value, 2019-2030

5.3.2 Europe Immune Thrombocytopenia Treatment Sales Value by Country (%), 2023 VS 2030

5.4 Asia Pacific

5.4.1 Asia Pacific Immune Thrombocytopenia Treatment Sales Value, 2019-2030

5.4.2 Asia Pacific Immune Thrombocytopenia Treatment Sales Value by Country (%), 2023 VS 2030

5.5 South America

5.5.1 South America Immune Thrombocytopenia Treatment Sales Value, 2019-2030

5.5.2 South America Immune Thrombocytopenia Treatment Sales Value by Country (%), 2023 VS 2030

5.6 Middle East & Africa

5.6.1 Middle East & Africa Immune Thrombocytopenia Treatment Sales Value, 2019-2030

5.6.2 Middle East & Africa Immune Thrombocytopenia Treatment Sales Value by Country (%), 2023 VS 2030

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Immune Thrombocytopenia Treatment Sales Value Growth Trends, 2019 VS 2023 VS 2030

6.2 Key Countries/Regions Immune Thrombocytopenia Treatment Sales Value

6.3 United States

6.3.1 United States Immune Thrombocytopenia Treatment Sales Value, 2019-2030

6.3.2 United States Immune Thrombocytopenia Treatment Sales Value by Type (%), 2023 VS 2030

6.3.3 United States Immune Thrombocytopenia Treatment Sales Value by Application, 2023 VS 2030

6.4 Europe

6.4.1 Europe Immune Thrombocytopenia Treatment Sales Value, 2019-2030

6.4.2 Europe Immune Thrombocytopenia Treatment Sales Value by Type (%), 2023 VS 2030

6.4.3 Europe Immune Thrombocytopenia Treatment Sales Value by Application, 2023 VS 2030

6.5 China

6.5.1 China Immune Thrombocytopenia Treatment Sales Value, 2019-2030

6.5.2 China Immune Thrombocytopenia Treatment Sales Value by Type (%), 2023 VS 2030

6.5.3 China Immune Thrombocytopenia Treatment Sales Value by Application, 2023 VS 2030

6.6 Japan

6.6.1 Japan Immune Thrombocytopenia Treatment Sales Value, 2019-2030

6.6.2 Japan Immune Thrombocytopenia Treatment Sales Value by Type (%), 2023 VS 2030

6.6.3 Japan Immune Thrombocytopenia Treatment Sales Value by Application, 2023 VS 2030

6.7 South Korea

6.7.1 South Korea Immune Thrombocytopenia Treatment Sales Value, 2019-2030

6.7.2 South Korea Immune Thrombocytopenia Treatment Sales Value by Type (%), 2023 VS 2030

6.7.3 South Korea Immune Thrombocytopenia Treatment Sales Value by Application, 2023 VS 2030

6.8 Southeast Asia

6.8.1 Southeast Asia Immune Thrombocytopenia Treatment Sales Value, 2019-2030

6.8.2 Southeast Asia Immune Thrombocytopenia Treatment Sales Value by Type (%), 2023 VS 2030

6.8.3 Southeast Asia Immune Thrombocytopenia Treatment Sales Value by Application, 2023 VS 2030

6.9 India

6.9.1 India Immune Thrombocytopenia Treatment Sales Value, 2019-2030

6.9.2 India Immune Thrombocytopenia Treatment Sales Value by Type (%), 2023 VS 2030

6.9.3 India Immune Thrombocytopenia Treatment Sales Value by Application, 2023 VS 2030

7 Company Profiles

7.1 CSL Behring

7.1.1 CSL Behring Profile

7.1.2 CSL Behring Main Business

7.1.3 CSL Behring Immune Thrombocytopenia Treatment Products, Services and Solutions

7.1.4 CSL Behring Immune Thrombocytopenia Treatment Revenue (US$ Million) & (2019-2024)

7.1.5 CSL Behring Recent Developments

7.2 Amgen

7.2.1 Amgen Profile

7.2.2 Amgen Main Business

7.2.3 Amgen Immune Thrombocytopenia Treatment Products, Services and Solutions

7.2.4 Amgen Immune Thrombocytopenia Treatment Revenue (US$ Million) & (2019-2024)

7.2.5 Amgen Recent Developments

7.3 F.Hoffmann-La Roche

7.3.1 F.Hoffmann-La Roche Profile

7.3.2 F.Hoffmann-La Roche Main Business

7.3.3 F.Hoffmann-La Roche Immune Thrombocytopenia Treatment Products, Services and Solutions

7.3.4 F.Hoffmann-La Roche Immune Thrombocytopenia Treatment Revenue (US$ Million) & (2019-2024)

7.3.5 Kyowa Hakko Kirin Recent Developments

7.4 Kyowa Hakko Kirin

7.4.1 Kyowa Hakko Kirin Profile

7.4.2 Kyowa Hakko Kirin Main Business

7.4.3 Kyowa Hakko Kirin Immune Thrombocytopenia Treatment Products, Services and Solutions

7.4.4 Kyowa Hakko Kirin Immune Thrombocytopenia Treatment Revenue (US$ Million) & (2019-2024)

7.4.5 Kyowa Hakko Kirin Recent Developments

7.5 Rigel Pharmaceuticals

7.5.1 Rigel Pharmaceuticals Profile

7.5.2 Rigel Pharmaceuticals Main Business

7.5.3 Rigel Pharmaceuticals Immune Thrombocytopenia Treatment Products, Services and Solutions

7.5.4 Rigel Pharmaceuticals Immune Thrombocytopenia Treatment Revenue (US$ Million) & (2019-2024)

7.5.5 Rigel Pharmaceuticals Recent Developments

7.6 Shionogi

7.6.1 Shionogi Profile

7.6.2 Shionogi Main Business

7.6.3 Shionogi Immune Thrombocytopenia Treatment Products, Services and Solutions

7.6.4 Shionogi Immune Thrombocytopenia Treatment Revenue (US$ Million) & (2019-2024)

7.6.5 Shionogi Recent Developments

7.7 Dova Pharmaceuticals

7.7.1 Dova Pharmaceuticals Profile

7.7.2 Dova Pharmaceuticals Main Business

7.7.3 Dova Pharmaceuticals Immune Thrombocytopenia Treatment Products, Services and Solutions

7.7.4 Dova Pharmaceuticals Immune Thrombocytopenia Treatment Revenue (US$ Million) & (2019-2024)

7.7.5 Dova Pharmaceuticals Recent Developments

7.8 Novartis

7.8.1 Novartis Profile

7.8.2 Novartis Main Business

7.8.3 Novartis Immune Thrombocytopenia Treatment Products, Services and Solutions

7.8.4 Novartis Immune Thrombocytopenia Treatment Revenue (US$ Million) & (2019-2024)

7.8.5 Novartis Recent Developments

7.9 Shire

7.9.1 Shire Profile

7.9.2 Shire Main Business

7.9.3 Shire Immune Thrombocytopenia Treatment Products, Services and Solutions

7.9.4 Shire Immune Thrombocytopenia Treatment Revenue (US$ Million) & (2019-2024)

7.9.5 Shire Recent Developments

7.10 Ligand Pharmaceuticals

7.10.1 Ligand Pharmaceuticals Profile

7.10.2 Ligand Pharmaceuticals Main Business

7.10.3 Ligand Pharmaceuticals Immune Thrombocytopenia Treatment Products, Services and Solutions

7.10.4 Ligand Pharmaceuticals Immune Thrombocytopenia Treatment Revenue (US$ Million) & (2019-2024)

7.10.5 Ligand Pharmaceuticals Recent Developments

7.11 GSK

7.11.1 GSK Profile

7.11.2 GSK Main Business

7.11.3 GSK Immune Thrombocytopenia Treatment Products, Services and Solutions

7.11.4 GSK Immune Thrombocytopenia Treatment Revenue (US$ Million) & (2019-2024)

7.11.5 GSK Recent Developments

7.12 Grifols Biologicals

7.12.1 Grifols Biologicals Profile

7.12.2 Grifols Biologicals Main Business

7.12.3 Grifols Biologicals Immune Thrombocytopenia Treatment Products, Services and Solutions

7.12.4 Grifols Biologicals Immune Thrombocytopenia Treatment Revenue (US$ Million) & (2019-2024)

7.12.5 Grifols Biologicals Recent Developments

7.13 Jiangsu Hengrui Pharmaceutical

7.13.1 Jiangsu Hengrui Pharmaceutical Profile

7.13.2 Jiangsu Hengrui Pharmaceutical Main Business

7.13.3 Jiangsu Hengrui Pharmaceutical Immune Thrombocytopenia Treatment Products, Services and Solutions

7.13.4 Jiangsu Hengrui Pharmaceutical Immune Thrombocytopenia Treatment Revenue (US$ Million) & (2019-2024)

7.13.5 Jiangsu Hengrui Pharmaceutical Recent Developments

8 Industry Chain Analysis

8.1 Immune Thrombocytopenia Treatment Industrial Chain

8.2 Immune Thrombocytopenia Treatment Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 Immune Thrombocytopenia Treatment Sales Model

8.5.2 Sales Channel

8.5.3 Immune Thrombocytopenia Treatment Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.2 Data Source

10.2 Author Details

10.3 Disclaimer

FEATURED COMPANIES

Amgen Inc

F.Hoffmann-La Roche

Kyowa Hakko Kirin

Rigel Pharmaceuticals

Shionogi

Dova Pharmaceuticals

Novartis

Ligand Pharmaceuticals

Jiangsu Hengrui Pharmaceutical

List of Tables

Table 1. Immune Thrombocytopenia Treatment Market Trends

Table 2. Immune Thrombocytopenia Treatment Market Drivers & Opportunity

Table 3. Immune Thrombocytopenia Treatment Market Challenges

Table 4. Immune Thrombocytopenia Treatment Market Restraints

Table 5. Global Immune Thrombocytopenia Treatment Revenue by Company (2019-2024) & (US$ Million)

Table 6. Global Immune Thrombocytopenia Treatment Revenue Market Share by Company (2019-2024)

Table 7. Key Companies Immune Thrombocytopenia Treatment Manufacturing Base Distribution and Headquarters

Table 8. Key Companies Immune Thrombocytopenia Treatment Product Type

Table 9. Key Companies Time to Begin Mass Production of Immune Thrombocytopenia Treatment

Table 10. Global Immune Thrombocytopenia Treatment Companies Market Concentration Ratio (CR5 and HHI)

Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Immune Thrombocytopenia Treatment as of 2023)

Table 12. Mergers & Acquisitions, Expansion Plans

Table 13. Global Immune Thrombocytopenia Treatment Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)

Table 14. Global Immune Thrombocytopenia Treatment Sales Value by Type (2019-2024) & (US$ Million)

Table 15. Global Immune Thrombocytopenia Treatment Sales Value by Type (2025-2030) & (US$ Million)

Table 16. Global Immune Thrombocytopenia Treatment Sales Market Share in Value by Type (2019-2024) & (%)

Table 17. Global Immune Thrombocytopenia Treatment Sales Market Share in Value by Type (2025-2030) & (%)

Table 18. Global Immune Thrombocytopenia Treatment Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)

Table 19. Global Immune Thrombocytopenia Treatment Sales Value by Application (2019-2024) & (US$ Million)

Table 20. Global Immune Thrombocytopenia Treatment Sales Value by Application (2025-2030) & (US$ Million)

Table 21. Global Immune Thrombocytopenia Treatment Sales Market Share in Value by Application (2019-2024) & (%)

Table 22. Global Immune Thrombocytopenia Treatment Sales Market Share in Value by Application (2025-2030) & (%)

Table 23. Global Immune Thrombocytopenia Treatment Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 24. Global Immune Thrombocytopenia Treatment Sales Value by Region (2019-2024) & (US$ Million)

Table 25. Global Immune Thrombocytopenia Treatment Sales Value by Region (2025-2030) & (US$ Million)

Table 26. Global Immune Thrombocytopenia Treatment Sales Value by Region (2019-2024) & (%)

Table 27. Global Immune Thrombocytopenia Treatment Sales Value by Region (2025-2030) & (%)

Table 28. Key Countries/Regions Immune Thrombocytopenia Treatment Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030

Table 29. Key Countries/Regions Immune Thrombocytopenia Treatment Sales Value, (2019-2024) & (US$ Million)

Table 30. Key Countries/Regions Immune Thrombocytopenia Treatment Sales Value, (2025-2030) & (US$ Million)

Table 31. CSL Behring Basic Information List

Table 32. CSL Behring Description and Business Overview

Table 33. CSL Behring Immune Thrombocytopenia Treatment Products, Services and Solutions

Table 34. Revenue (US$ Million) in Immune Thrombocytopenia Treatment Business of CSL Behring (2019-2024)

Table 35. CSL Behring Recent Developments

Table 36. Amgen Basic Information List

Table 37. Amgen Description and Business Overview

Table 38. Amgen Immune Thrombocytopenia Treatment Products, Services and Solutions

Table 39. Revenue (US$ Million) in Immune Thrombocytopenia Treatment Business of Amgen (2019-2024)

Table 40. Amgen Recent Developments

Table 41. F.Hoffmann-La Roche Basic Information List

Table 42. F.Hoffmann-La Roche Description and Business Overview

Table 43. F.Hoffmann-La Roche Immune Thrombocytopenia Treatment Products, Services and Solutions

Table 44. Revenue (US$ Million) in Immune Thrombocytopenia Treatment Business of F.Hoffmann-La Roche (2019-2024)

Table 45. F.Hoffmann-La Roche Recent Developments

Table 46. Kyowa Hakko Kirin Basic Information List

Table 47. Kyowa Hakko Kirin Description and Business Overview

Table 48. Kyowa Hakko Kirin Immune Thrombocytopenia Treatment Products, Services and Solutions

Table 49. Revenue (US$ Million) in Immune Thrombocytopenia Treatment Business of Kyowa Hakko Kirin (2019-2024)

Table 50. Kyowa Hakko Kirin Recent Developments

Table 51. Rigel Pharmaceuticals Basic Information List

Table 52. Rigel Pharmaceuticals Description and Business Overview

Table 53. Rigel Pharmaceuticals Immune Thrombocytopenia Treatment Products, Services and Solutions

Table 54. Revenue (US$ Million) in Immune Thrombocytopenia Treatment Business of Rigel Pharmaceuticals (2019-2024)

Table 55. Rigel Pharmaceuticals Recent Developments

Table 56. Shionogi Basic Information List

Table 57. Shionogi Description and Business Overview

Table 58. Shionogi Immune Thrombocytopenia Treatment Products, Services and Solutions

Table 59. Revenue (US$ Million) in Immune Thrombocytopenia Treatment Business of Shionogi (2019-2024)

Table 60. Shionogi Recent Developments

Table 61. Dova Pharmaceuticals Basic Information List

Table 62. Dova Pharmaceuticals Description and Business Overview

Table 63. Dova Pharmaceuticals Immune Thrombocytopenia Treatment Products, Services and Solutions

Table 64. Revenue (US$ Million) in Immune Thrombocytopenia Treatment Business of Dova Pharmaceuticals (2019-2024)

Table 65. Dova Pharmaceuticals Recent Developments

Table 66. Novartis Basic Information List

Table 67. Novartis Description and Business Overview

Table 68. Novartis Immune Thrombocytopenia Treatment Products, Services and Solutions

Table 69. Revenue (US$ Million) in Immune Thrombocytopenia Treatment Business of Novartis (2019-2024)

Table 70. Novartis Recent Developments

Table 71. Shire Basic Information List

Table 72. Shire Description and Business Overview

Table 73. Shire Immune Thrombocytopenia Treatment Products, Services and Solutions

Table 74. Revenue (US$ Million) in Immune Thrombocytopenia Treatment Business of Shire (2019-2024)

Table 75. Shire Recent Developments

Table 76. Ligand Pharmaceuticals Basic Information List

Table 77. Ligand Pharmaceuticals Description and Business Overview

Table 78. Ligand Pharmaceuticals Immune Thrombocytopenia Treatment Products, Services and Solutions

Table 79. Revenue (US$ Million) in Immune Thrombocytopenia Treatment Business of Ligand Pharmaceuticals (2019-2024)

Table 80. Ligand Pharmaceuticals Recent Developments

Table 81. GSK Basic Information List

Table 82. GSK Description and Business Overview

Table 83. GSK Immune Thrombocytopenia Treatment Products, Services and Solutions

Table 84. Revenue (US$ Million) in Immune Thrombocytopenia Treatment Business of GSK (2019-2024)

Table 85. GSK Recent Developments

Table 86. Grifols Biologicals Basic Information List

Table 87. Grifols Biologicals Description and Business Overview

Table 88. Grifols Biologicals Immune Thrombocytopenia Treatment Products, Services and Solutions

Table 89. Revenue (US$ Million) in Immune Thrombocytopenia Treatment Business of Grifols Biologicals (2019-2024)

Table 90. Grifols Biologicals Recent Developments

Table 91. Jiangsu Hengrui Pharmaceutical Basic Information List

Table 92. Jiangsu Hengrui Pharmaceutical Description and Business Overview

Table 93. Jiangsu Hengrui Pharmaceutical Immune Thrombocytopenia Treatment Products, Services and Solutions

Table 94. Revenue (US$ Million) in Immune Thrombocytopenia Treatment Business of Jiangsu Hengrui Pharmaceutical (2019-2024)

Table 95. Jiangsu Hengrui Pharmaceutical Recent Developments

Table 96. Key Raw Materials Lists

Table 97. Raw Materials Key Suppliers Lists

Table 98. Immune Thrombocytopenia Treatment Downstream Customers

Table 99. Immune Thrombocytopenia Treatment Distributors List

Table 100. Research Programs/Design for This Report

Table 101. Key Data Information from Secondary Sources

Table 102. Key Data Information from Primary Sources

Table 103. Business Unit and Senior & Team Lead Analysts

List of Figures

Figure 1. Immune Thrombocytopenia Treatment Product Picture

Figure 2. Global Immune Thrombocytopenia Treatment Sales Value, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global Immune Thrombocytopenia Treatment Sales Value (2019-2030) & (US$ Million)

Figure 4. Immune Thrombocytopenia Treatment Report Years Considered

Figure 5. Global Immune Thrombocytopenia Treatment Players Revenue Ranking (2023) & (US$ Million)

Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Immune Thrombocytopenia Treatment Revenue in 2023

Figure 7. Immune Thrombocytopenia Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 8. Corticosteroids Picture

Figure 9. Intravenous Immunoglobulin (IVIG) Picture

Figure 10. Anti-D Immunoglobulin Picture

Figure 11. Thrombopoietin Receptor Agonist (TPO-RA) Picture

Figure 12. Others Picture

Figure 13. Global Immune Thrombocytopenia Treatment Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)

Figure 14. Global Immune Thrombocytopenia Treatment Sales Value Market Share by Type, 2023 & 2030

Figure 15. Product Picture of Hospitals and Clinics

Figure 16. Product Picture of Research and Academic Institutes

Figure 17. Product Picture of Others

Figure 18. Global Immune Thrombocytopenia Treatment Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)

Figure 19. Global Immune Thrombocytopenia Treatment Sales Value Market Share by Application, 2023 & 2030

Figure 20. North America Immune Thrombocytopenia Treatment Sales Value (2019-2030) & (US$ Million)

Figure 21. North America Immune Thrombocytopenia Treatment Sales Value by Country (%), 2023 VS 2030

Figure 22. Europe Immune Thrombocytopenia Treatment Sales Value (2019-2030) & (US$ Million)

Figure 23. Europe Immune Thrombocytopenia Treatment Sales Value by Country (%), 2023 VS 2030

Figure 24. Asia Pacific Immune Thrombocytopenia Treatment Sales Value (2019-2030) & (US$ Million)

Figure 25. Asia Pacific Immune Thrombocytopenia Treatment Sales Value by Country (%), 2023 VS 2030

Figure 26. South America Immune Thrombocytopenia Treatment Sales Value (2019-2030) & (US$ Million)

Figure 27. South America Immune Thrombocytopenia Treatment Sales Value by Country (%), 2023 VS 2030

Figure 28. Middle East & Africa Immune Thrombocytopenia Treatment Sales Value (2019-2030) & (US$ Million)

Figure 29. Middle East & Africa Immune Thrombocytopenia Treatment Sales Value by Country (%), 2023 VS 2030

Figure 30. Key Countries/Regions Immune Thrombocytopenia Treatment Sales Value (%), (2019-2030)

Figure 31. United States Immune Thrombocytopenia Treatment Sales Value, (2019-2030) & (US$ Million)

Figure 32. United States Immune Thrombocytopenia Treatment Sales Value by Type (%), 2023 VS 2030

Figure 33. United States Immune Thrombocytopenia Treatment Sales Value by Application (%), 2023 VS 2030

Figure 34. Europe Immune Thrombocytopenia Treatment Sales Value, (2019-2030) & (US$ Million)

Figure 35. Europe Immune Thrombocytopenia Treatment Sales Value by Type (%), 2023 VS 2030

Figure 36. Europe Immune Thrombocytopenia Treatment Sales Value by Application (%), 2023 VS 2030

Figure 37. China Immune Thrombocytopenia Treatment Sales Value, (2019-2030) & (US$ Million)

Figure 38. China Immune Thrombocytopenia Treatment Sales Value by Type (%), 2023 VS 2030

Figure 39. China Immune Thrombocytopenia Treatment Sales Value by Application (%), 2023 VS 2030

Figure 40. Japan Immune Thrombocytopenia Treatment Sales Value, (2019-2030) & (US$ Million)

Figure 41. Japan Immune Thrombocytopenia Treatment Sales Value by Type (%), 2023 VS 2030

Figure 42. Japan Immune Thrombocytopenia Treatment Sales Value by Application (%), 2023 VS 2030

Figure 43. South Korea Immune Thrombocytopenia Treatment Sales Value, (2019-2030) & (US$ Million)

Figure 44. South Korea Immune Thrombocytopenia Treatment Sales Value by Type (%), 2023 VS 2030

Figure 45. South Korea Immune Thrombocytopenia Treatment Sales Value by Application (%), 2023 VS 2030

Figure 46. Southeast Asia Immune Thrombocytopenia Treatment Sales Value, (2019-2030) & (US$ Million)

Figure 47. Southeast Asia Immune Thrombocytopenia Treatment Sales Value by Type (%), 2023 VS 2030

Figure 48. Southeast Asia Immune Thrombocytopenia Treatment Sales Value by Application (%), 2023 VS 2030

Figure 49. India Immune Thrombocytopenia Treatment Sales Value, (2019-2030) & (US$ Million)

Figure 50. India Immune Thrombocytopenia Treatment Sales Value by Type (%), 2023 VS 2030

Figure 51. India Immune Thrombocytopenia Treatment Sales Value by Application (%), 2023 VS 2030

Figure 52. Immune Thrombocytopenia Treatment Industrial Chain

Figure 53. Immune Thrombocytopenia Treatment Manufacturing Cost Structure

Figure 54. Channels of Distribution (Direct Sales, and Distribution)

Figure 55. Bottom-up and Top-down Approaches for This Report

Figure 56. Data Triangulation

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$3950

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions